Randomized trial · people
Tesamorelin had little effect on simvastatin and ritonavir levels
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In healthy volunteers, tesamorelin barely changed blood levels of simvastatin and ritonavir.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2013
- Journal
- Clin Pharmacol Drug Dev
What they tested
The team tested whether tesamorelin changes CYP3A activity by checking its effect on blood levels of simvastatin and ritonavir.
How the study was done
Two randomized, two-way crossover studies in healthy volunteers, where each person had both treatments in turn. In one treatment, people took 2 mg tesamorelin on Days 1-7 plus a single 80 mg simvastatin or 100 mg ritonavir dose on Day 6; in the other, they took the simvastatin or ritonavir dose alone on Day 6.

What they found
For simvastatin, the ratios of total exposure (AUC, the drug's total amount in the blood over time) and peak level (Cmax) with versus without tesamorelin, along with their 90% confidence intervals, all stayed inside the standard 80-125% no-effect range. For ritonavir, total exposure also stayed inside that range, but the lower bound for peak level was 74.8%, pointing to a lower peak. The ritonavir ratios were about 90%, which the team judged a minor drop. They concluded that tesamorelin's effect on CYP3A activity was minimal, if any.
What it doesn’t show
These were short studies in healthy volunteers, with a single dose of each partner drug given on Day 6 of a 7-day tesamorelin course. They don't show what happens in patients, with long-term use, or with other medicines.
The paper
Teng et al. Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers. Clin Pharmacol Drug Dev. 2013.
The compound
More studies on Tesamorelin
- Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophyMeta-analysis · people · 2026
- Tesamorelin shifted liver gene activity in HIV-related fatty liverRandomized trial · people · 2020
- Tesamorelin: denser, larger trunk muscles at 26 weeks in HIVRandomized trial · people · 2019
- Tesamorelin: no change in glucose control in type 2 diabetesRandomized trial · people · 2017
- Tesamorelin cut visceral and liver fat over 6 months in HIV patientsRandomized trial · people · 2014
- Tesamorelin cut visceral fat 15.4% vs placebo in HIV at 26 weeksRandomized trial · people · 2010
- Every study on Tesamorelin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.